Carcinoma News and Research RSS Feed - Carcinoma News and Research

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.
Study focuses on improving therapeutic outcomes in cancer patients through diet-drug combination

Study focuses on improving therapeutic outcomes in cancer patients through diet-drug combination

Boosting anti-cancer immunity through diet and novel drug therapies—that's the idea behind a collaborative project involving researchers from the South Dakota State University College of Pharmacy and Sanford Research in Sioux Falls. [More]
EORTC researchers review potential treatment options for patients with locally advanced breast cancer

EORTC researchers review potential treatment options for patients with locally advanced breast cancer

Treating patients with locally advanced inoperable breast cancer is an extremely difficult task. The overwhelming majority of patients treated for this disease suffer relapse and, despite the best multimodal treatment, do not survive. There is a medical need to examine current and potential treatments, and EORTC researchers have recently published an article in Nature Reviews Clinical Oncology concerning this topic. [More]
ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. [More]
Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years). [More]
Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent (sunitinib) or Nexavar (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence, the ECOG-ACRIN Cancer Research Group announced. [More]
New HPV vaccine has potential to prevent 90% of conditions triggered by HPV

New HPV vaccine has potential to prevent 90% of conditions triggered by HPV

A new vaccine against HPV infections has the potential to prevent 90 per cent of all of the conditions triggered by the human papillomavirus. These are the findings of a randomised, controlled, international study involving a new, 9-component vaccine against HPV used on more than 14,000 young women aged between 16 and 26 years. [More]
Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2014, including a summary of recent corporate highlights. [More]
Researchers identify molecule that plays key role in aggressive thyroid cancer, other cancers

Researchers identify molecule that plays key role in aggressive thyroid cancer, other cancers

Cancer researchers at Mayo Clinic's campus in Jacksonville, Florida, have identified a molecule they say is important to survival of anaplastic thyroid carcinoma (ATC) — a lethal tumor with no effective therapies. [More]
MD Anderson Cancer Center to host annual Making Cancer History seminar in Sarasota

MD Anderson Cancer Center to host annual Making Cancer History seminar in Sarasota

The University of Texas MD Anderson Cancer Center returns March 7 to Sarasota, Fla., for the institution's annual Making Cancer History® seminar at the Hyatt Regency Sarasota, 1000 Blvd. of the Arts. [More]
Wistar researchers identify new therapeutic target for aggressive form of ovarian cancer

Wistar researchers identify new therapeutic target for aggressive form of ovarian cancer

Ovarian cancer is the deadliest of all cancers affecting the female reproductive system with very few effective treatments available. Prognosis is even worse among patients with certain subtypes of the disease. Now, researchers at The Wistar Institute have identified a new therapeutic target in a particularly aggressive form of ovarian cancer, paving the way for what could be the first effective targeted therapy of its kind for the disease. [More]
New laser technology shows promise for cancer treatment

New laser technology shows promise for cancer treatment

Surgeons rely on 200-year-old technology when removing cancer--sight and touch--to determine how much to remove and what to leave alone. Laser technology pioneered at Florida Atlantic University has the promise to help a surgeon better determine if an area is cancer or healthy tissue. Moreover, when combined with laser treatment for cancer, this work lays the groundwork for laser robotic treatment of cancer. [More]
Researchers develop novel strategy in fight against cancer

Researchers develop novel strategy in fight against cancer

A team of researchers led by Associate Professor Caroline Lee from the Yong Loo Lin School of Medicine at the National University of Singapore, in collaboration with Associate Professor Song Jianxing of the Department of Biological Sciences at the NUS Faculty of Science, has developed a novel strategy in the fight against cancer. [More]
Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). [More]
Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Timing may be decisive when it comes to overcoming cancer's ability to evade treatment. By hitting breast cancer cells with a targeted therapeutic immediately after chemotherapy, researchers from Brigham and Women's Hospital (BWH) were able to target cancer cells during a transitional stage when they were most vulnerable, killing cells and shrinking tumors in the lab and in pre-clinical models. [More]
Freiburg researchers identify novel approach to inhibit signalling processes in colorectal cancer cells

Freiburg researchers identify novel approach to inhibit signalling processes in colorectal cancer cells

Colorectal carcinoma is the most frequent type of bowel cancer and the second most common tumour disease among men and women in Germany. So-called microsatellite stable colorectal cancer with mutations in the BRAF gene represents a particularly aggressive form. [More]
Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

A study led by researchers at the Institute for Molecular Medicine Finland FIMM and Faculty of Medicine, University of Helsinki and the Helsinki University Central Hospital Comprehensive Cancer Center, in close collaboration with researchers at Pfizer, has identified a previously unrecognized action of Pfizer's axitinib as a potent inhibitor of the dominant mutation that confers drug resistance to all well tolerated treatments in patients with certain types of leukemia. [More]
Radiation therapy more effective at preventing recurrence of ductal carcinoma in situ

Radiation therapy more effective at preventing recurrence of ductal carcinoma in situ

In a surprising finding, a collaborative national clinical trials group (RTOG) including Dartmouth-Hitchcock's Alan Hartford, MD, PhD, discovered that radiation therapy in addition to chemotherapy was even more effective at preventing recurrence of ductal carcinoma in situ (DCIS) than previously thought. [More]
Scientists potentially discover new therapeutic targets to halt progression of tumor cells

Scientists potentially discover new therapeutic targets to halt progression of tumor cells

Chronic inflammation is directly associated with several types of cancer, yet the reasons as to why this happens at a cellular level remain unclear. Now, an international team of scientists led by researchers at The Wistar Institute has identified a multistep process showing not only how these cancers develop but also potentially discovering new therapeutic targets that could halt the formation and progression of tumor cells. [More]
Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV"). [More]
ECOG-ACRIN Cancer Research Group opens clinical trial for women with newly diagnosed DCIS

ECOG-ACRIN Cancer Research Group opens clinical trial for women with newly diagnosed DCIS

In direct response to recommendations made by a National Institutes of Health scientific consensus panel, the ECOG-ACRIN Cancer Research Group announced today the opening of E4112, a clinical trial for women with newly diagnosed ductal carcinoma in situ (DCIS) of the breast who, together with their doctors, will use the results of a magnetic resonance imaging (MRI) exam to determine whether to undergo a lumpectomy or a mastectomy. [More]